| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,180,000 |
| Market
Cap: |
56.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.48 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TCR2 Therapeutics is a clinical-stage cell therapy company developing T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its TCR Fusion Construct T cells (TRuC-T cells). Co.'s TRuC-T cells recognize and kill cancer cells by using the entire TCR signaling complex. Co.'s TRuC-T cell targeting mesothelin-expressing solid tumors are: gavocabtagene autoleucel, in which Co. is conducting its clinical trial to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma or cholangiocarcinoma; and TC-510, which incorporates a PD-1:CD28 chimeric switch receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
121,863 |
468,513 |
| Total Buy Value |
$0 |
$0 |
$226,133 |
$885,368 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
140,340 |
287,401 |
| Total Sell Value |
$0 |
$0 |
$263,840 |
$445,404 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
33 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gibson Neil W |
Director |
– • – |
2019-11-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(217,974) |
79,640 |
|
- |
|
| Gibson Neil W |
Director |
– • – |
2019-11-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(196,177) |
297,614 |
|
- |
|
| Gibson Neil W |
Director |
– • – |
2019-11-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(212,560) |
493,791 |
|
- |
|
| F2 - Tpo Investments Llc |
10% Owner |
– – • |
2019-10-22 |
4 |
S |
$15.16 |
$58,931 |
I/I |
(3,888) |
1,409,571 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-09-23 |
4 |
S |
$17.31 |
$195,982 |
I/I |
(11,321) |
1,411,656 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-09-20 |
4 |
S |
$17.94 |
$7,263,837 |
I/I |
(405,000) |
1,417,172 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-09-04 |
4 |
S |
$17.55 |
$214,414 |
I/I |
(12,214) |
102,563 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-09-03 |
4 |
S |
$17.01 |
$179,653 |
I/I |
(10,559) |
114,777 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2019-08-30 |
4 |
A |
$12.75 |
$10,748 |
D/D |
843 |
843 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2019-08-30 |
4 |
A |
$12.75 |
$12,495 |
D/D |
980 |
980 |
|
- |
|
| Somaiya Mayur Ian |
Chief Financial Officer |
• – – |
2019-08-30 |
4 |
A |
$12.75 |
$21,242 |
D/D |
1,666 |
1,666 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-29 |
4 |
S |
$17.01 |
$62,925 |
I/I |
(3,700) |
125,336 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-28 |
4 |
S |
$17.01 |
$113,941 |
I/I |
(6,700) |
129,036 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-27 |
4 |
S |
$17.01 |
$20,414 |
I/I |
(1,200) |
135,736 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-26 |
4 |
S |
$17.01 |
$495,479 |
I/I |
(29,128) |
136,936 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-23 |
4 |
S |
$17.00 |
$51 |
I/I |
(3) |
166,064 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-22 |
4 |
S |
$17.03 |
$1,703 |
I/I |
(100) |
166,067 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-08-21 |
4 |
S |
$17.00 |
$8,500 |
I/I |
(500) |
166,167 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
B |
$15.00 |
$10,000,005 |
I/I |
666,667 |
536,962 |
1.5 |
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
2,904,594 |
403,629 |
|
- |
|
| Mpm Sunstates Gp Managing Member Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
B |
$15.00 |
$10,599,990 |
I/I |
706,666 |
4,050,865 |
1.5 |
- |
|
| Mpm Sunstates Gp Managing Member Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
3,148,297 |
3,344,199 |
|
- |
|
| Mpm Asset Management Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
B |
$15.00 |
$10,599,990 |
I/I |
706,666 |
4,050,865 |
1.5 |
- |
|
| Mpm Asset Management Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
3,148,297 |
3,344,199 |
|
- |
|
| China Molybdenum (hong Kong) Co Ltd |
10% Owner |
– – • |
2019-02-19 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
2,137,419 |
1.5 |
- |
|
132 Records found
|
|
Page 5 of 6 |
|
|
